Shire Plc has agreed to buy US group NPS Pharmaceuticals Inc for $5.2 billion, the Dublin-based drugmaker’s biggest acquisition yet as it seeks to strengthen its position in the lucrative field of medicines for rare diseases.

The takeover continues the breakneck pace of deal-making seen last year in the pharma­ceuticals sector, as companies jockey for promising assets amid a wave of new drugs emerging from research laboratories, and Shire’s chief executive, Flemming Ornskov, told Reuters he would keep looking for more deals to grow the company into a biotech powerhouse.

Shire will pay $46 per NPS share, representing a premium of nearly 10 per cent to NPS’s Friday close, the two companies said on Sunday.

The move will not come as a huge surprise, since Shire was first linked to NPS in May 2014. When plans for Shire to sell itself to AbbVie Inc fell apart in October, Shire said it could take another look at previous deal prospects and reports of Shire’s interest resurfaced in mid-December.

“This is about growth and rare diseases, and it fits hand in glove with our strategy and our franchise,” Ornskov said.

Shire expects the all-cash deal to add to its adjusted earnings from 2016 onward. It believes it can achieve cost savings of approximately 25 per cent to 35 per cent of consensus forecasts for NPS’s standalone future operating cost base from 2017.

Analysts at Jefferies said the deal could boost earnings per share from 2016 by at least 12 per cent. Shares in Shire edged slightly lower in morning trade yesterday, however, since the NPS deal is likely to reduce talk of Shire as a takeover target.

The acquisition of New Jersey-based NPS will give Shire two significant new drugs. Gattex, a treatment for short-bowel syndrome (SBS), is already on the market, while Natpara, for hypoparathyroidism, is awaiting approval from the US Food and Drug Administration.

The FDA is expected to decide on the Natpara application by January 24.

“I am confident that Natpara will be approved on the 24th, however ... there is absolutely no guarantee,” said NPS’s chief executive, Francois Nader. “Given our interactions with the FDA, I believe it will be approved.”

Nader called Shire’s decision to conclude a deal before a decision a calculated risk on their part that nevertheless “would provide the joint company the opportunity to deploy the most resources in supporting the launch”.

The consensus of analysts’ forecasts for the two NPS medicines point to annual sales of $509 million and $534 million respectively by 2019, according to Thomson Reuters Cortellis, although Ornskov believes they may bring in more.

“Both of them have significant sales potential and some have mentioned the word ‘blockbuster’,” he said. The term blockbuster applies to a drug with sales of $1 billion or more.

The drugs treat serious but rare disorders, which means they can command high prices. SBS is a potentially fatal gastrointestinal disorder that can leave patients dependent on intravenous feeding, while hypoparathyroidism is an endocrine disease cause by absent or damaged parathyroid glands.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.